451 related articles for article (PubMed ID: 35455472)
1. Levetiracetam Mechanisms of Action: From Molecules to Systems.
Contreras-García IJ; Cárdenas-Rodríguez N; Romo-Mancillas A; Bandala C; Zamudio SR; Gómez-Manzo S; Hernández-Ochoa B; Mendoza-Torreblanca JG; Pichardo-Macías LA
Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455472
[TBL] [Abstract][Full Text] [Related]
2. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
[TBL] [Abstract][Full Text] [Related]
3. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.
Surges R; Volynski KE; Walker MC
Ther Adv Neurol Disord; 2008 Jul; 1(1):13-24. PubMed ID: 21180561
[TBL] [Abstract][Full Text] [Related]
4. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
[TBL] [Abstract][Full Text] [Related]
5. Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug.
Cortes-Altamirano JL; Olmos-Hernández A; Bonilla-Jaime H; Bandala C; González-Maciel A; Alfaro-Rodríguez A
Neurol India; 2016; 64(6):1266-1275. PubMed ID: 27841198
[TBL] [Abstract][Full Text] [Related]
6. Mode of seizure inhibition by sodium channel blockers, an SV2A ligand, and an AMPA receptor antagonist in a rat amygdala kindling model.
Wu T; Ido K; Ohgoh M; Hanada T
Epilepsy Res; 2019 Aug; 154():42-49. PubMed ID: 31035244
[TBL] [Abstract][Full Text] [Related]
7. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
[TBL] [Abstract][Full Text] [Related]
8. Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.
Contreras-García IJ; Gómez-Lira G; Phillips-Farfán BV; Pichardo-Macías LA; García-Cruz ME; Chávez-Pacheco JL; Mendoza-Torreblanca JG
Brain Sci; 2021 Apr; 11(5):. PubMed ID: 33922424
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.
Yamagata A; Ito K; Suzuki T; Dohmae N; Terada T; Shirouzu M
Nat Commun; 2024 Apr; 15(1):3027. PubMed ID: 38637505
[TBL] [Abstract][Full Text] [Related]
10. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
[TBL] [Abstract][Full Text] [Related]
11. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Gillard M
Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
[TBL] [Abstract][Full Text] [Related]
13. Levetiracetam inhibits THP-1 monocyte chemotaxis and adhesion via the synaptic vesicle 2A.
Zhang Y; Hu M; Tang YY; Zhang B; Han YY; Huang ZY; Chen C; Li G
Biochem Biophys Res Commun; 2020 Feb; ():. PubMed ID: 32067739
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M
Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430
[TBL] [Abstract][Full Text] [Related]
15. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
[TBL] [Abstract][Full Text] [Related]
16. Levetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking.
García-Pérez E; Mahfooz K; Covita J; Zandueta A; Wesseling JF
Epilepsia; 2015 Apr; 56(4):535-45. PubMed ID: 25684406
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors.
Newton HB; Dalton J; Goldlust S; Pearl D
J Neurooncol; 2007 Sep; 84(3):293-6. PubMed ID: 17431542
[TBL] [Abstract][Full Text] [Related]
18. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Sands ZA; Vandenplas C; Gillard M
Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam resistance: Synaptic signatures & corresponding promoter SNPs in epileptic hippocampi.
Grimminger T; Pernhorst K; Surges R; Niehusmann P; Priebe L; von Lehe M; Hoffmann P; Cichon S; Schoch S; Becker AJ
Neurobiol Dis; 2013 Dec; 60():115-25. PubMed ID: 24018139
[TBL] [Abstract][Full Text] [Related]
20. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model.
Talos DM; Chang M; Kosaras B; Fitzgerald E; Murphy A; Folkerth RD; Jensen FE
Pediatr Res; 2013 Jan; 73(1):24-30. PubMed ID: 23138400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
